| 彭滔.氨磺必利联合氟伏沙明治疗强迫症患者临床疗效观察及安全性[J].浙江中西医结合杂志,2019,29(3): |
| 氨磺必利联合氟伏沙明治疗强迫症患者临床疗效观察及安全性 |
| Clinical efficacy and safety of amisapride combined with fluvoxamine in the treatment of obsessive-compulsive disorderPeng Tao Yiwu mental health center psychiatric department 322000 |
| 投稿时间：2018-07-04 修订日期：2018-08-12 |
| DOI： |
| 中文关键词: 氨磺必利 氟伏沙明 强迫症 疗效 安全性 |
| 英文关键词:amisapride fluvoxamine obsessive compulsive disorder efficacy safety. |
| 基金项目: |
|
| 摘要点击次数: 1086 |
| 全文下载次数: 14 |
| 中文摘要: |
| 目的：探讨氨磺必利联合氟伏沙明治疗强迫症患者临床疗效观察及安全性。方法：哪的95例强迫症患者,按照随机表法分为观察组49例与对照组46例。观察组采用氨磺必利联合氟伏沙明治疗,对照组采用氟伏沙明治疗。两组疗程均为12周。比较两组治疗疗效,治疗前后Yale-Browm强迫量表评分、汉密尔顿抑郁量表(HAMD)24项和汉密尔顿焦虑量表(HAMA)14项评分变化,及药物副反应发生情况。结果：观察组治疗总有效率(81.63%)高于对照组(63.04%),且有统计学差异(P<0.05)。两组治疗后强迫行为、强迫思维和总分较治疗前降低(观察组：t=39.823、23.416、56.832,对照组：t=24.299、17.259、28.681,P<0.05)；观察组治疗后强迫行为、强迫思维和总分低于对照组(t=24.922、8.756、19.574,P<0.05)。两组治疗后HAMD和HAMA评分较治疗前降低(观察组：t=18.551、21.163,对照组：t=15.649、16.199,P<0.05)；观察组治疗后HAMD和HAMA评分低于对照组(t=8.927、9.363,P<0.05)。两组药物副反应发生率比较无统计学差异(P>0.05)。结论：氨磺必利联合氟伏沙明治疗强迫症患者临床疗效明显,且用药安全性良好,值得临床借鉴。 |
| 英文摘要: |
| Objective: To explore the clinical efficacy and safety of amisapride combined with fluvoxamine in the treatment of obsessive-compulsive disorder. Methods: 95 cases of obsessive-compulsive disorder admitted to our hospital were selected and divided into observation group (49 cases) and control group (46 cases) according to random table. The observation group was treated with amisapride combined with fluvoxamine, while the control group was treated with fluvoxamine. The two groups were treated for 12 weeks. The curative effect of the two groups was compared, the scores of the Yale-Browm compulsion scale, the 24 items of Hamilton Depression Scale (HAMD) and the Hamilton Anxiety Scale (HAMA) were changed before and after the treatment, and the occurrence of the side effects of the drug was observed. Results: the total effective rate of the observation group (81.63%) was higher than that of the control group (63.04%) (P<0.05). After treatment, the forced behavior, forced thinking and total score of the two groups were lower than before treatment (observation group:t=39.823, 23.416, 56.832, control group: t=24.299, 17.259, 28.681, P<0.05), and the forced behavior, forced thinking and total score of the observation group were lower than those of the control group (t=24.922, 8.756, 19.574, P<0.05). After treatment, the scores of HAMD and HAMA were lower in the two groups than before the treatment (the observation group: t=18.551, 21.163, the control group: t=15.649, 16.199, P<0.05), and the HAMD and HAMA scores in the observation group were lower than those of the control group (t=8.927, 9.363, P<0.05). There was no significant difference in the incidence of side effects between the two groups (P>0.05). Conclusion: amisapride combined with fluvoxamine in the treatment of obsessive-compulsive disorder has obvious clinical efficacy, and the drug safety is good, which is worthy of clinical reference. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
